A notable advancement in glucose care is emerging with the approval of tirzepatide in a 45mg form. This new offering builds upon the existing success of tirzepatide, a dual GIP and GLP-1 target, and offers a https://rsakref104218.tusblogos.com/41344821/groundbreaking-development-tirzepatide-45mg-for-glucose-control